Europe pays to lose its spin-outs

Much of European deep tech and life sciences know-how is going to the US – that’s the conclusion reached by the world’s first Europe-wide market analysis of university deep tech and life sciences spin-outs. While 86% of those firms’ seed funding came from Europe, 48% of their late-stage financing and almost 61% of exits took place across the Atlantic. In other words, European taxpayers are funding value creation in the US – an uncomfortable thought in today’s geopolitical climate.

Further topics in this issue:

• Europe’s moment: We could be the heroes of biotech – Antoine Papiernik,  Sofinnova Partner
• NATO elevates biotech to defence priority
• EU trilog nears deal on CRISPR crop rules
• EU Commission unveils new bioeconomy strategy
• MorphoSys acquisition by Novartis takes an unexpected path
• Taking the laurels in the bispecifics race: PD-(L)1 x VEGF
• UK sets ambitious course to phase out animal testing
• UK hikes drug prices after pharma exodus
• 1st spin-outs report
• Europe’s early innovation crunch
• Interview: Ruth Shah, Head of Bayer Co.Lab Berlin
• BioSpain: What US investors are seeking in Europe
• BIO-Europe: Europe’s early innovation crunch
• Drug delivery services: New vectors on the bloc
• SLAS focus:Why CDMOs are racing to automate quality control
• Selecting a CDMO for custom-activated PEGs
• New target kills IBD-causing bacteria in the gut
• Melatonin effective against ageing and Alzheimer’s; Shielding salivary glands; Metabolic syndrome triggers Parkinson’s disease
• CDX2 knock-out improves liver organoids
• News from associations/clinical trials/
• BioFairs COMPASS  including: World ADC Congress, London (UK, 2026); BIO Europe Spring, Lisbon (Portugal, 2026); GMP Pharma Congress, Wiesbaden (Germany 2026); bio:cap Investival, Berlin (Germany 2026), SLAS, Boston (USA, 2026)